Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024

Author(s):

Sikander Ailawadhi, MD, discusses how emerging trends in targeted therapies, immunotherapies, and precision medicine presented at ASH 2024 are addressing unmet needs in the management of hematologic cancers and shaping future treatment strategies.

Now Viewing

EP: 1.Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024

EP: 2.Insights on CLL and SLL Treatment with BTK Inhibitors: Patient Preferences and Shared Decision-Making

EP: 3.Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences

EP: 4.Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients

EP: 5.Advancing Hematologic Care and the Future of Shared Decision-Making

Video content above is prompted by the following:

Coming into ASH 2024, what would you consider to be the largest unmet needs in the management of hematologic cancers?
What are the latest trends and innovations you have observed in the treatment and management of hematologic cancers leading up to and coming out of ASH 2024?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!